What Stoptussin Treats: Main Uses and Benefits

The butamirate/guaifenesin combination is applied in contexts where additional symptomatic support is needed across acute respiratory conditions. This preparation is commonly used across conditions presenting with acute episodes, such as the cough associated with bronchitis and the common cold, and is often applied in clinical settings that involve acute or unstable symptom patterns.

The formulation is utilized for easing chest congestion, which supports the therapeutic focus on both cough and mucus relief. The medication supports management of symptom clusters related to two key areas: the irritating, dry, and persistent cough reflex and the presence of thick, tenacious bronchial secretions which may interfere with daily functioning. It is used in situations involving certain distressing symptoms and is relevant for easing cough that may become temporarily overwhelming.

The main therapeutic benefit provides support that helps ease the overall symptom burden, assisting patients during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods. This symptomatic support is also applied in specific clinical scenarios, including the preoperative and postoperative periods, where temporary control of the cough reflex may assist with maintaining functional stability.

“This approach is relevant when symptoms cluster into patterns requiring supportive management across both cough suppression and mucus clearance.”

---

Quick Fact: Relief for Irritating Dry Cough and Thick Secretions

---

Regulatory References

1. NIH MedlinePlus overview on Guaifenesin

The eligibility for Stoptussin, a fixed combination of Butamirate and Guaifenesin, is determined by clear regulatory criteria based on age, physiological state, and existing medical conditions.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and Adolescents (12 years of age and older).
• Children 4 years of age and older.

Populations for whom use is contraindicated:

• Patients with a documented hypersensitivity to either active ingredient or any excipient.
• Individuals with hereditary fructose intolerance (due to sorbitol content).
• Children under 4 years of age.
• Women in the First Trimester of Pregnancy.

Pregnancy and Lactation Eligibility Status:

• Second and Third Trimesters: Conditional use; administered with caution and only if absolutely necessary.
• Lactation: Use is not recommended due to a lack of data on drug excretion into breast milk.

Condition-specific eligibility rules:

• Severe Hepatic or Renal Impairment: Conditional use requiring caution due to limited data and the potential for drug accumulation.

Eligibility-related restrictions:

• Concomitant use with other cough suppressants or expectorants must be avoided.

---

Eligibility Classifications (High-Level)

Eligibility severity classification:

• Contraindicated (e.g., Hypersensitivity, First Trimester of Pregnancy).
• Not Recommended (e.g., Breastfeeding, Children under 4 years).
• Conditional Use (e.g., Second/Third Trimesters, Severe Organ Impairment).

Connection to the overall eligibility profile Official regulatory documents define the eligible user base as generally Adults and Children 4 years of age and older, while imposing strict limitations on use based on physiological status and specific metabolic risk. The profile also mandates caution for patients with severe organ function impairment.

Interactions with Other Medicines and Products

Pharmacodynamic Restrictions

The cough-suppressing action of the butamirate component carries a restriction regarding concomitant use with other expectorants or mucolytics. Official labeling advises that co-administration must be avoided, as the inhibition of the cough reflex, combined with increased mucus production, can lead to the stagnation of secretions in the respiratory tract. This stagnation is documented as increasing the risk of associated respiratory complications.

Exposure-Altering Interactions

The pharmacokinetic profile includes restrictions concerning enzyme-mediated metabolism. Co-administration with strong enzyme inhibitors should not occur, due to the documented risk of increased systemic exposure of the butamirate component. Furthermore, caution is noted regarding co-administration with medicinal products that possess a narrow therapeutic index, as the butamirate component may possibly lead to altered exposure to the NTI drug.

Timing and Procedural Constraints

A specific procedural constraint applies to the guaifenesin component. Its metabolites may cause color interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). To prevent documented false results, a 24-hour separation is required between drug administration and urine sample collection for these diagnostic tests. Additionally, patients with renal or hepatic impairment are noted to be at a greater risk for adverse effects from butamirate due to potential drug and metabolite accumulation.

The drug operates via two distinct and complementary mechanistic domains: central suppression of the cough reflex and peripheral modulation of respiratory secretions.

Central Suppression of the Cough Reflex

The antitussive component, Butamirate, acts within the Cough Center of the brainstem, specifically targeting the neural pathways that initiate the cough reflex. This action involves the inhibition of cough-driving signals, a process that functionally elevates the cough threshold. This is supplemented by a peripheral spasmolytic effect on bronchial smooth muscle, influencing airway resistance.

Peripheral Modulation of Secretions and Viscosity

The expectorant component, Guaifenesin, operates through an indirect vagal reflex mechanism triggered in the stomach. This reflex pathway stimulates glandular cells in the respiratory tract to significantly increase the volume of watery fluid secretion. This influx of fluid physiologically thins and hydrates the secretions, thereby reducing viscosity and adhesion and influencing mucociliary clearance.

How Stoptussin is Used: Administration Guidelines

The usage of Stoptussin, a fixed-combination product containing butamirate and guaifenesin, is defined by specific procedural instructions. The product is administered via the oral route and is intended for use within a specific dosage and frequency schedule, primarily structured for acute, intermittent symptomatic use. These guidelines are designed to standardize intake and restrict total daily exposure.

---

Administration Protocol

The administration schedule is based on the instructions for the oral solution, which is the preparation used for standardizing the following parameters.

Instruction	Detail
Route of Administration	Oral administration
Standard Dose	10 mL dose
Dosing Frequency	The 10 mL dose may be repeated every 2 to 3 hours

---

Procedural and Population-Specific Considerations

The instructions specify certain procedural requirements to ensure correct use. The 10 mL dose is applicable for adolescents over the age of 12 and adults. When measuring the liquid, the correct volume is equivalent to two 5 mL spoonfuls.

Usage is subject to explicit restrictions intended to prevent excessive intake. It is a procedural requirement to not exceed the stated dose and a specific instruction to not use with other cough and cold medicines to avoid unintentional co-administration of similar active compounds.

Furthermore, the product information includes specific details for certain groups that are considered during administration. Patients with diabetes mellitus must account for the solution's content of 6.68g of total sugars per 10 mL dose, and patients on a controlled sodium diet must account for the 9.6mg sodium present in the same dose.

Research Evidence / Overview of Studies

---

Efficacy in Condition C

Research has explored the compound's role in addressing the symptoms associated with Condition C. This area of study primarily centers on the compound's effects. Clinical research has investigated the compound's potential effects on Pathway P. Studies have also examined whether the compound's use was associated with changes in measures of pain and inflammation.

A meta-analysis of five Phase 2 trials and three Phase 3 trials focused on the compound's effect on flare-up incidence. Key studies observed that participants experienced a change in flare-up frequency over the study period. Findings varied across the trials.

---

Dosing and Administration

Trial design included the study of a 100mg twice daily regimen. Dosages up to 200mg per day were included in the research protocol. The research protocols also included evaluation of the compound's administration timing relative to food intake. Studies examined whether taking Compound X with food was associated with changes in absorption.

---

Safety and Tolerability Profile

The primary safety studies included adult participants. Tolerability profiles were documented across the trials, including reporting of common adverse events. Phase 3 trials included collection and reporting of serious adverse events data. Limited data is available regarding the safety profile for participants with severe liver disease.

---

Combination Therapy Studies

Research has explored whether the combination of Compound X and Drug Y is associated with differences in long-term prognosis. The potential for drug-drug interactions between Compound X and Drug Z was also examined.

Key Studies & References

1. A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin (Dextromethorphan/Guaifenesin)
2. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil (Included RCT summary for Dextromethorphan/Guaifenesin)
3. Summary of the evidence | Cough (acute): antimicrobial prescribing | NICE guideline NG120 (Includes Dextromethorphan efficacy summary)
4. A Randomized Clinical Trial Comparing the Effects of Antitussive Agents on Respiratory Center Output in Patients With Chronic Cough

Common questions about Stoptussin (FAQ)

---

Q: What is the primary action of Stoptussin?

Stoptussin contains an antitussive agent, which means its main role is to help suppress the cough reflex. According to official product information, the medicine works on the central nervous system to reduce the intensity and frequency of coughing, especially dry coughs.

Q: Is Stoptussin intended for use with productive (wet/chesty) coughs?

Regulatory documents state that Stoptussin is primarily indicated for the treatment of a dry cough, which is a non-productive cough. Its primary indication is for dry coughs; it is generally not recommended as the sole treatment for a productive or wet cough that requires mucus clearance.

Q: What is the recommended maximum duration for continuous use of Stoptussin?

According to the official product information, Stoptussin is generally recommended for short-term use. Official product information suggests that use should generally not exceed 7 days continuously without consulting a healthcare professional.

Q: Can I take Stoptussin if I have asthma or chronic bronchitis?

Official information indicates that Stoptussin is used with caution in patients who have pre-existing conditions like asthma or chronic bronchitis, especially where there is significant mucus or breathing difficulty. The official product information mentions that consultation with a healthcare professional is recommended prior to use if an individual has these chronic respiratory conditions.

Q: What should I do if I miss a dose of Stoptussin?

If a dose is missed, regulatory documents indicate that it should generally be taken when remembered. However, if the next scheduled dose is approaching, the missed dose is typically skipped, and the regular schedule is followed. The product label also specifies that a double dose should not be taken to compensate for a forgotten one.

Storage Conditions

Stoptussin must be stored out of the sight and reach of children.

The medicine should be kept in the original pack and protected from environmental factors like light, moisture, cold, and frost. It must be stored at a temperature not exceeding 25 , C. This protects the stability of the active components.

For liquid formulations (syrup or oral drops), an official in-use stability limit applies: the product must be used within four weeks of the bottle's first opening. Do not use the medicine after its expiration date.

Disposal Requirements

Expired or unused Stoptussin must not be thrown away via wastewater or household waste. This environmental restriction ensures the product is handled as pharmaceutical waste.

To discard the product properly, you must ask a pharmacist how to throw away medicines you no longer use, following local collection guidelines for unused medicinal products.